Arcus Biosciences, Inc. (RCUS)
|52 Week Range||15.7-36.13|
|1y Target Est||-|
|DCF Unlevered||RCUS DCF ->|
|DCF Levered||RCUS LDCF ->|
|Debt / Equity||10.07%||Neutral|
Upgrades & Downgrades
Latest RCUS news
Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
29 August 2023
Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and a l...
Stock movers: Nvidia, iTeos, Arcus, Manchester United, Nike, AMC, Bath & Body Works and more
23 August 2023
Nvidia: calm before the storm There's a calm before storm ahead of today's hotly-anticipated quarterly financials, albeit Nvidia stock is up US$9.17 or 2% changing hands at US$465.75. Expectations are...
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates
7 August 2023
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.93 per share a year ago.
3 Biotech Stocks to Buy for Long-Term Gains
13 July 2023
Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated ...
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
9 May 2023
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $0.96 per share a year ago.
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
28 February 2023
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 6.06% and 45.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto...
Buy 3 Top Profitable Stocks Using Net Income Ratio
14 February 2023
Arcus Biosciences (RCUS), Suzano (SUZ), and Arch Resources (ARCH) has been selected as the top picks with a high net income ratio.
Down -45.21% in 4 Weeks, Here's Why Arcus Biosciences, Inc. (RCUS) Looks Ripe for a Turnaround
12 January 2023
The heavy selling pressure might have exhausted for Arcus Biosciences, Inc. (RCUS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall St...
Arcus Biosciences, Gilead Sciences shares fall as new lung cancer drug data fails to meet investor e...
20 December 2022
Arcus Biosciences Inc and Gilead Sciences Inc shares have both taken a tumble after the companies reported positive but not groundbreaking results from a Phase 2 trial involving its new lung cancer dr...
Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug
20 December 2022
Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that ...